Cell-El Therapeutics Ltd. was incorporated in Israel in 2014 after two years of scientific investigations. Our research aims to assess the relationship between autism spectrum disorders (ASD) and elements of the immune system to identify the underlying mechanisms that might cause ASD. Once diagnostic biomarkers will have been identified, Cell-El’s mission is to develop a targeted immunotherapy for ASD.